EUCTR2017-004295-55-SI进行中（未招募）1 期
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must satisfy the following criteria to be enrolled in the study:
- •1. Subjects who are not in clinical response and/or clinical remission after completing 12 weeks in the Induction Studies RPC01-3201 or RPC01-3202, subjects who experience relapse in the Maintenance Study RPC01-3203, subjects who complete the Maintenance Study RPC01-3203, subjects who complete at least 1 year of RPC01 2201.
- •2. Subject should not have any constraints under local regulations, must provide written informed consent prior to any studyrelated procedures, and must have the ability to comply with the Table of Events.
- •3. Female subjects of childbearing potential (FCBP):
- •Note: For the purposes of this study, a female subject is considered to be of childbearing potential if she 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been postmenopausal for at least 24 consecutive months (that is, has had menses at any time during the preceding 24 consecutive months).
- •Must agree to practice a highly effective method of contraception throughout the study until completion of the 90-day Safety Follow-up Visit. Highly effective methods of contraception are those that alone or in combination result in a failure rate of a Pearl Index of less than 1% per year when used consistently and correctly. Examples of acceptable methods of birth control in the study are the following:
- •combined hormonal (containing oestrogen and progestogen) contraception, which may be oral, intravaginal, or transdermal
- •progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, or implantable
- •placement of an intrauterine device (IUD)
- •placement of an intrauterine hormone-releasing system (IUS)
- •bilateral tubal occlusion
- •vasectomized partner
- •complete sexual abstinence
- •Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not acceptable methods of contraception.
- •Female condom and male condom should not be used together.
- •Counseling about pregnancy precautions and the potential risks of fetal exposure must be conducted for FCBP. The Investigator will educate all FCBP about the different options of contraceptive methods or abstinence at Day 1, as appropriate.
- •The subject will be re-educated every time her contraceptive measures/methods or ability to become pregnant changes. The female subject's chosen form of contraception must be effective by the time the female subject starts the study (for example, hormonal contraception should be initiated at least 28 days before Day 1).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1080
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 120
排除标准
- •The presence of any of the following will exclude a subject from enrollment:
- •4.3.1. Exclusions Related to General Health:
- •1. Subject has any clinically relevant cardiovascular, hepatic, neurological, pulmonary [severe respiratory disease (pulmonary fibrosis or chronic obstructive pulmonary disease)], ophthalmological, endocrine, psychiatric, or other major systemic disease making implementation of the protocol or interpretation of the study difficult or that would put the subject at risk by participating in the study.
- •2. Subject is pregnant, lactating, or has a positive urine beta human chorionic gonadotropin (ß-hCG) test.
- •3. Subject has suspected or diagnosed intra-abdominal or perianal abscess that has not been appropriately treated.
- •4.3.2. Exclusions Related to Medications:
- •4. Hypersensitivity to active ingredients or excipients of ozanimod
- •5. Subject has received any of the following therapies since the first dose of IP in the prior ozanimod study:
- •treatment with a biologic agent as well as other treatments for CD such as etrasimod, filgotinib, upadacitinib
- •treatment with an investigational agent other than ozanimod
- •treatment with D-penicillamine, leflunomide, thalidomide, natalizumab, fingolimod or other S1P modulators
- •treatment with lymphocyte-depleting therapies (eg, Campath®, anti-CD4, cladribine, rituximab, ocrelizumab, cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation, alemtuzumab, daclizumab)
- •6. Subject is currently receiving or requires initiation of any of the following therapies:
- •treatment with corticosteroids at a dose that exceeds the prednisone equivalent of >40 mg
- •treatment with immunomodulatory agents (eg, AZA, 6-MP, or MTX)
- •chronic non-steroidal anti-inflammatory drug (NSAID) use (note: occasional use of NSAIDs and acetaminophen [eg, headache, arthritis, myalgias, or menstrual cramps] and aspirin up to 325 mg/day is permitted)
- •treatment with Class Ia or Class III anti-arrhythmic drugs, treatment with 2 or more agents in combination known to prolong PR interval, or treatment with additional prohibited systemic cardiac medication
- •treatment with breast cancer resistance protein (BCRP) inhibitors (eg, cyclosporine, eltrombopag)
- •7. Subject is receiving treatment with any of the following drugs or interventions within the corresponding timeframe:
- •CYP2C8 inhibitors (eg, gemfibrozil or clopidogrel) and inducers (eg, rifampicin)
- •Monoamine oxidase inhibitors (eg, selegiline, phenelzine)
- •4.3.3. Exclusions Related to Laboratory Resultsand Other Assessments:
- •8. Subject has any clinically significant abnormal results (eg, labs or ECG) which, in the opinion of the Investigator, may put the subject at risk.
- •9. Subjects has a pre-dose resting HR < 55 bpm. One recheck is allowed at the Day 1 visit. If HR remains < 55 bpm at Day 1, one additional recheck is allowed at a later date within the available window for roll-over from the previous study.
研究者
相似试验
进行中（未招募）
1 期
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s DiseaseEUCTR2017-004295-55-BECelgene International II Sàrl1,200
进行中（未招募）
1 期
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s DiseaseEUCTR2017-004295-55-ITCELGENE INTERNATIONAL II SàR1,350
进行中（未招募）
1 期
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-004295-55-DECelgene International II Sàrl1,200
已完成
3 期
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn*s Diseasebowel diseaseimmune-mediated inflammatory disease of the gastrointestinal tract10017969NL-OMON56255Celgene International II Sàrl12
进行中（未招募）
1 期
Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia GravisMedDRA version: 20.0Level: LLTClassification code 10028415Term: MyastheniaSystem Organ Class: 100000004859Generalized Myasthenia GravisEUCTR2019-001565-33-PLRa Pharmaceuticals, Inc. (now part of UCB)200